Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2007 4
2008 9
2009 23
2010 45
2011 67
2012 61
2013 91
2014 116
2015 164
2016 164
2017 193
2018 213
2019 225
2020 306
2021 386
2022 408
2023 394
2024 352

Text availability

Article attribute

Article type

Publication date

Search Results

2,872 results

Results by year

Filters applied: . Clear all
Page 1
Advances in systemic therapies for triple negative breast cancer.
Leon-Ferre RA, Goetz MP. Leon-Ferre RA, et al. BMJ. 2023 May 30;381:e071674. doi: 10.1136/bmj-2022-071674. BMJ. 2023. PMID: 37253507 Review.
Triple negative breast cancer (TNBC) continues to be the subtype of breast cancer with the highest rates of recurrence and mortality. ...In the operable setting, efforts to improve outcomes have focused on escalation of systemic therap …
Triple negative breast cancer (TNBC) continues to be the subtype of breast cancer with the highest …
Triple-Negative Breast Cancer and Predictive Markers of Response to Neoadjuvant Chemotherapy: A Systematic Review.
van den Ende NS, Nguyen AH, Jager A, Kok M, Debets R, van Deurzen CHM. van den Ende NS, et al. Int J Mol Sci. 2023 Feb 3;24(3):2969. doi: 10.3390/ijms24032969. Int J Mol Sci. 2023. PMID: 36769287 Free PMC article. Review.
Around 40-50% of all triple-negative breast cancer (TNBC) patients achieve a pathological complete response (pCR) after treatment with neoadjuvant chemotherapy (NAC). ...In addition, our review reveals proteomic, genomic and transcriptomic marke …
Around 40-50% of all triple-negative breast cancer (TNBC) patients achieve a pathological complete response (pCR …
Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing.
Kim C, Gao R, Sei E, Brandt R, Hartman J, Hatschek T, Crosetto N, Foukakis T, Navin NE. Kim C, et al. Cell. 2018 May 3;173(4):879-893.e13. doi: 10.1016/j.cell.2018.03.041. Epub 2018 Apr 19. Cell. 2018. PMID: 29681456 Free PMC article.
Triple-negative breast cancer (TNBC) is an aggressive subtype that frequently develops resistance to chemotherapy. ...To investigate this question, we applied single-cell DNA and RNA sequencing in addition to bulk exome sequencing to profile longitudin …
Triple-negative breast cancer (TNBC) is an aggressive subtype that frequently develops resistance to chemotherap …
Adjuvant and Neoadjuvant Treatment of Triple-Negative Breast Cancer With Chemotherapy.
Marra A, Curigliano G. Marra A, et al. Cancer J. 2021 Jan-Feb 01;27(1):41-49. doi: 10.1097/PPO.0000000000000498. Cancer J. 2021. PMID: 33475292 Review.
Triple-negative breast cancer (TNBC) accounts for 15% to 20% of all invasive breast carcinomas and is defined by the lack of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2. Although TNBC is characterized b …
Triple-negative breast cancer (TNBC) accounts for 15% to 20% of all invasive breast carcinomas and is def …
KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer.
Rizzo A, Cusmai A, Acquafredda S, Giovannelli F, Rinaldi L, Misino A, Palmiotti G. Rizzo A, et al. Future Oncol. 2022 Jun;18(18):2301-2309. doi: 10.2217/fon-2021-1647. Epub 2022 Apr 5. Future Oncol. 2022. PMID: 35378995 Review.
Stage I-III triple-negative breast cancer accounts for approximately 15-20% of new diagnoses of early breast cancer. ...Herein we will provide an overview of recent clinical studies of neoadjuvant immune checkpoint inhibitors in pa …
Stage I-III triple-negative breast cancer accounts for approximately 15-20% of new diagnoses of early breast …
An overview of triple-negative breast cancer.
Kumar P, Aggarwal R. Kumar P, et al. Arch Gynecol Obstet. 2016 Feb;293(2):247-69. doi: 10.1007/s00404-015-3859-y. Epub 2015 Sep 4. Arch Gynecol Obstet. 2016. PMID: 26341644 Review.
PURPOSE: Triple-negative breast cancer (TNBC) is a heterogeneous group of tumors comprising various breast cancers simply defined by the absence of estrogen receptor, progesterone receptor and overexpression of human epidermal growth factor rece …
PURPOSE: Triple-negative breast cancer (TNBC) is a heterogeneous group of tumors comprising various breast …
Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.
Lehmann BD, Jovanović B, Chen X, Estrada MV, Johnson KN, Shyr Y, Moses HL, Sanders ME, Pietenpol JA. Lehmann BD, et al. PLoS One. 2016 Jun 16;11(6):e0157368. doi: 10.1371/journal.pone.0157368. eCollection 2016. PLoS One. 2016. PMID: 27310713 Free PMC article.
Triple-negative breast cancer (TNBC) is a heterogeneous disease that can be classified into distinct molecular subtypes by gene expression profiling. Considered a difficult-to-treat cancer, a fraction of TNBC patients benefit significantly from …
Triple-negative breast cancer (TNBC) is a heterogeneous disease that can be classified into distinct molecular s …
Triple-negative breast cancer: recent treatment advances.
Bergin ART, Loi S. Bergin ART, et al. F1000Res. 2019 Aug 2;8:F1000 Faculty Rev-1342. doi: 10.12688/f1000research.18888.1. eCollection 2019. F1000Res. 2019. PMID: 31448088 Free PMC article. Review.
Triple-negative breast cancer (TNBC) is a breast cancer subtype renowned for its capacity to affect younger women, metastasise early despite optimal adjuvant treatment and carry a poor prognosis. Neoadjuvant therapy has focu …
Triple-negative breast cancer (TNBC) is a breast cancer subtype renowned for its capacity to affec …
Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis.
Poggio F, Bruzzone M, Ceppi M, Pondé NF, La Valle G, Del Mastro L, de Azambuja E, Lambertini M. Poggio F, et al. Ann Oncol. 2018 Jul 1;29(7):1497-1508. doi: 10.1093/annonc/mdy127. Ann Oncol. 2018. PMID: 29873695 Free article.
BACKGROUND: The role of platinum-based neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) patients is highly controversial and it is not endorsed by current guidelines. ...Platinum-based neoadjuvant chemotherapy may be consi …
BACKGROUND: The role of platinum-based neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) p …
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study.
Gianni L, Huang CS, Egle D, Bermejo B, Zamagni C, Thill M, Anton A, Zambelli S, Bianchini G, Russo S, Ciruelos EM, Greil R, Semiglazov V, Colleoni M, Kelly C, Mariani G, Del Mastro L, Maffeis I, Valagussa P, Viale G. Gianni L, et al. Ann Oncol. 2022 May;33(5):534-543. doi: 10.1016/j.annonc.2022.02.004. Epub 2022 Feb 17. Ann Oncol. 2022. PMID: 35182721 Free article. Clinical Trial.
BACKGROUND: High-risk triple-negative breast cancers (TNBCs) are characterized by poor prognosis, rapid progression to metastatic stage and onset of resistance to chemotherapy, thus representing an area in need of new therapeutic approaches. ...The primary ai …
BACKGROUND: High-risk triple-negative breast cancers (TNBCs) are characterized by poor prognosis, rapid progression to …
2,872 results